NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...
NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...
Business Activity Index at 54.2%; New Orders Index at 51.3%; Employment Index at 47.2%; Supplier Deliveries Index at 50.3%
TEMPE, Ariz., July 3, 2025 /PRNewswire/...
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.